logo-loader

Midatech Pharma chief: Ophthotech deal “significant piece of business”

Published: 23:48 13 Aug 2015 AEST

The chief executive of Midetech Pharma (LON:MTPH), Jim Phillips, provides more detail on the firm’s collaboration with US–listed Ophthotech Corporation (NASDAQ:OPHT).

Both firms will work on new treatments for macular degeneration of the eyes.

No financial terms were released, but Midatech said the agreement underpins a significant amount of the market forecasts of revenue for 2015.

Philips also updates on the firm’s takeover of Nasdaq-listed DARA Biosciences (NASDAQ:DARA). The AIM-listed company told investors earlier this week that the deal is progressing, having filed a F-4 registration form.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

11 hours, 17 minutes ago